Battle over eye medicine gives drugmaker a dose of reality.
Hayden
Erika Check
EC
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004339:Drug Compounding; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab